Vector VestAdvertisement Vector VestAdvertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MyDogBuster, Dip66, locksflooring, roberteliates, HorseShoe Man, sup105
Search This Board:
Last Post: 1/24/2015 5:31:03 PM - Followers: 579 - Board type: Free - Posts Today: 0
MultiCell Technologies (MCET) 
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
 Office: (401) 762-0045



Ticker - MCET (U.S. Reporting: SEC Filer) 

Estimated outstanding shares: 4.3 Billion a/o October 2014

Estimated Float: 3.97 Billion a/o October 2014

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)



Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development

 MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.

                                       MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.

 MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.

 MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

Therapeutic Candidate  


Discovery Optimization    

Preclinical Development    

Phase 1    

Phase 2/b   

Phase 3    



X X X X  



X X      



X X      



X X      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations

W. Gerald Newmin, Chairman and Chief Executive Officer
Mr. W. Gerald Newmin joined the Company in June 1995.  Mr. Newmin currently serves as Chairman of the Board of Directors and Acting Chief Executive Officer of the Company.  Mr. Newmin is also Chairman and CEO, and a director of Xenogenics Corporation, a majority-owned subsidiary of the Company; Chairman and CEO, and a director of MCT Rhode Island Corp., a wholly-owned subsidiary of the Company; and, CEO and a director of MultiCell Immunotherapeutics, Inc., a majority-owned subsidiary of the Company.  Mr. Newmin has managed NYSE and American Stock Exchange Fortune 500 companies.  Mr. Newmin has been President of Health America Corporation, then the nation’s largest publicly held HMO management company.  Mr. Newmin was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured.  Mr. Newmin was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive.  Mr. Newmin was instrumental in Whittaker’s entry into the US and international health care markets.  Mr. Newmin was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States.  Mr. Newmin retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003.  Mr. Newmin has a Bachelors degree in Accounting from Michigan State University.



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Additional Proxy Soliciting Materials (definitive) (defa14a) 01/23/2015 04:36:20 PM
MCET News: Proxy Statement (definitive) (def 14a) 12/12/2014 03:03:36 PM
MCET News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 12/02/2014 10:24:10 AM
MCET News: Quarterly Report (10-q) 10/15/2014 12:34:25 PM
MCET News: MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer 08/25/2014 08:51:00 AM
#39289  Sticky Note Voting Right e-mail sup105 01/21/15 03:00:13 PM
#34376  Sticky Note MultiCell Technologies, Inc. OTCQB TraderpennyX 04/03/14 03:57:31 AM
#27347  Sticky Note PATENT INFORMATION roberteliates 03/28/13 07:50:04 AM
#39308   They probably going to release the revote proxy sup105 01/24/15 05:31:03 PM
#39307   Sounds fishy too I bet no one voted sup105 01/24/15 05:30:06 PM
#39306   Sounds like if nescessary to revote then Tambra3077 01/24/15 12:30:30 PM
#39305   WHY WOULD MCET REVOKE OUR VOTES! Stockholders locksflooring 01/24/15 09:34:17 AM
#39304   They postponed the meeting to feb 4th sup105 01/23/15 03:15:09 PM
#39303   I don't think they got the votes to ztek 01/23/15 02:32:53 PM
#39302   I think Mr. Newmin was ousted? The HorseShoe Man 01/23/15 08:53:07 AM
#39301   Slow day today. Waiting for what is ztek 01/22/15 03:21:54 PM
#39300   I doubt anybody went to this meeting today nutriman24 01/22/15 02:48:18 PM
#39299   Naw think about it sup105 01/22/15 12:30:38 PM
#39298   is it public company? sup105 01/22/15 12:28:41 PM
#39297   LOL They didn't put any new candidate sup105 01/22/15 12:27:51 PM
#39296   Is anyone going to the meeting today? ztek 01/22/15 12:03:39 PM
#39295   At least they are making serious money on nutriman24 01/22/15 11:28:52 AM
#39294   There's only two. simon wagstaff 01/22/15 10:33:25 AM
#39293   The entire staff needs to be wiped out Dip66 01/22/15 08:11:16 AM
#39292   Kick all of them out especially newmin Turtledip 01/22/15 02:51:50 AM
#39291   Proposal(s) Recommendations of the Board of Directors Vote Options sup105 01/21/15 05:59:21 PM
#39290   Be part of this action and vote guys =) sup105 01/21/15 03:02:20 PM
#39289   Voting Right e-mail sup105 01/21/15 03:00:13 PM
#39288   All aboard! HorseShoe Man 01/21/15 02:32:51 PM
#39287   Yeah, I am still here too. Just OrnateSilk 01/21/15 02:08:03 PM
#39286   Well, that didn't last long. simon wagstaff 01/21/15 11:09:31 AM
#39285   Can someone post the dial in number for Dip66 01/21/15 10:23:01 AM
#39284   I thought today was the meeting but it's HorseShoe Man 01/21/15 09:36:21 AM
#39283   . .I am coming back in bontooth 01/21/15 03:28:38 AM
#39281   There is no company left in my opinion. Dip66 01/20/15 03:17:02 PM
#39280   Honestly this company have lot of shit to sup105 01/20/15 01:06:31 PM
#39279   I seen a lot in penny land that Tambra3077 01/20/15 01:00:00 PM
#39278   Do you think MCET is going to go HorseShoe Man 01/20/15 12:53:53 PM
#39277 peacbywar 01/20/15 12:09:09 PM
#39276   Is that a Bull or Bear perspective ? Erin Laundry 01/20/15 11:34:07 AM
#39275   what makes you think that? just curios Tambra3077 01/20/15 11:30:14 AM
#39274   Tomorrow morning could be very beautiful here at HorseShoe Man 01/20/15 11:19:14 AM
#39273   It's on the rise day of or after Turtledip 01/16/15 03:18:46 PM
#39272   Starting to think the 3's are done with HorseShoe Man 01/16/15 02:56:46 PM
#39271   100k shares? Almost as if the MM's are HorseShoe Man 01/16/15 12:41:45 PM
#39270   Something's getting ready to break loose HorseShoe Man 01/16/15 12:35:25 PM
#39269   lots of M&A in pharma right now ztek 01/16/15 11:53:14 AM
#39268   Stock market is closed Monday I think HorseShoe Man 01/16/15 10:23:18 AM
#39267   Before hours Tuesday or Wednesday for a massive PR HorseShoe Man 01/16/15 10:20:20 AM
#39266   I don't think MCET is going to go HorseShoe Man 01/16/15 10:16:30 AM
#39265   It's a penny stock. Chances are 100% It's 1gumbi 01/16/15 07:49:27 AM
#39263   He is basher sup105 01/15/15 01:35:16 PM
#39262   none Why do people seek for RS? sup105 01/15/15 01:34:18 PM
#39261   You just saw the future =) sup105 01/15/15 01:33:26 PM
#39260   Lol ahaha Turtledip 01/15/15 12:23:08 PM
#39259   None........ Thanks For The Honesty.............. mwv 01/15/15 09:18:31 AM
#39257   Thanks For The Response........... What's The Future Here................ mwv 01/15/15 08:33:17 AM
#39255   What's The Chance Of A RS Here.............. mwv 01/15/15 08:26:55 AM